Larimar TherapeuticsLRMR
LRMR
About: Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
Employees: 65
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
432% more call options, than puts
Call options by funds: $2.13M | Put options by funds: $400K
38% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 32
1.41% less ownership
Funds ownership: 100.81% [Q3] → 99.4% (-1.41%) [Q4]
7% less funds holding
Funds holding: 123 [Q3] → 115 (-8) [Q4]
19% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 27
42% less capital invested
Capital invested by funds: $421M [Q3] → $245M (-$176M) [Q4]
67% less funds holding in top 10
Funds holding in top 10: 3 [Q3] → 1 (-2) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$10
424%
upside
Avg. target
$17.50
816%
upside
High target
$26
1,261%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Guggenheim Yatin Suneja 18% 1-year accuracy 6 / 34 met price target | 1,261%upside $26 | Buy Reiterated | 25 Mar 2025 |
Baird Joel Beatty 21% 1-year accuracy 8 / 38 met price target | 424%upside $10 | Outperform Maintained | 25 Mar 2025 |
HC Wainwright & Co. Edward White 24% 1-year accuracy 36 / 149 met price target | 738%upside $16 | Buy Maintained | 25 Mar 2025 |
Truist Securities Joon Lee 41% 1-year accuracy 17 / 41 met price target | 842%upside $18 | Buy Initiated | 29 Jan 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
3 weeks ago
Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results
BALA CYNWYD, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its fourth quarter and full year 2024 operating and financial results.
Neutral
GlobeNewsWire
1 month ago
Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference
BALA CYNWYD, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company's management team will present and participate in 1x1 investor meetings at the Leerink Partners Global Healthcare Conference, taking place in Miami Beach, FL from March 10 – 12, 2025.
Neutral
GlobeNewsWire
2 months ago
Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia
BALA CYNWYD, Pa., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that dosing of adolescents 12-17 years old has started in the Company's pediatric PK run-in study for patients with Friedreich's ataxia (FA).
Positive
Seeking Alpha
3 months ago
Larimar Therapeutics: Positive Friedreich's Ataxia Data Can Only Get Better
Larimar Therapeutics, Inc. reported initial positive data from phase 2 long-term OLE study using nomlabofusp for treatment of patients with Friedreich's Ataxia; Increase of tissue FXN protein levels from 15% to 30%. The global Friedreich's Ataxia market size is projected to reach $2.06 billion by 2030. Additional data using higher 50 mg dose of nomlabofusp to treat patients with Friedreich's Ataxia expected in mid-2025.
Neutral
Benzinga
4 months ago
What's Going On With Larimar Therapeutics Stock On Tuesday?
On Monday, Larimar Therapeutics, Inc. LRMR released initial data from the ongoing long-term OLE study evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver in participants with Friedreich's Ataxia.
Neutral
Benzinga
4 months ago
Why Is Larimar Therapeutics Stock Trading Lower On Monday?
On Monday, Larimar Therapeutics, Inc. LRMR released initial data from the ongoing long-term OLE study evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver in participants with Friedreich's Ataxia.
Neutral
GlobeNewsWire
4 months ago
Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich's Ataxia
BALA CYNWYD, Pa., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced positive initial data from the ongoing long-term OLE study evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver in participants with FA. The Company also provided a nomlabofusp development program update.
Positive
Zacks Investment Research
5 months ago
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance
Madrigal, Corcept, Catalyst Larimar and Theravance have been highlighted in this Industry Outlook article.
Positive
Zacks Investment Research
5 months ago
5 Small Drug Stocks to Buy as Trump Gets Re-Elected
Innovation is at its peak for the Zacks Medical-Drugs industry. MDGL, CORT, CPRX, LRMR and TBPH may prove to be good additions to one's portfolio.
Positive
Zacks Investment Research
5 months ago
Wall Street Analysts Think Larimar (LRMR) Could Surge 192.89%: Read This Before Placing a Bet
The mean of analysts' price targets for Larimar (LRMR) points to a 192.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Charts implemented using Lightweight Charts™